Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 1.00 |
| ▸ | GNA15 | P30679 | 1/20 | 0.75 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.75 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.75 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.75 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16249163 | 0.94 | FFAR1 (0.89) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL15125767 | 0.94 | FFAR1 (0.89) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL3450662 | 0.94 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL1633142 | 0.93 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16684725 | 0.93 | FFAR1 (0.86) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16690557 | 0.91 | FFAR1 (0.91) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL13110442 | 0.90 | FFAR1 (0.82) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL1634874 | 0.89 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL15125882 | 0.89 | FFAR1 (0.85) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL15125719 | 0.89 | FFAR1 (0.85) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932289-B2 | Remedy for diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20080319077-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-12-25 | — | — | US | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319077-A1 | Remedy for Diabetes | GPR119, GLP1R, GPR65 | FFAR1 19/4885GNA15 1108/4885SLC10A1 171/4885 |
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | FFAR1 93/4885GNA15 1685/4885SLC10A1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.